In case of ovarian cancer, BRCA1 and BRCA2 patients exhibit a differential age of tumor development—BRCA1 carriers develop tumors earlier than those carrying BRCA2 mutations (48 vs. 57 years). Here, BRCA2 is linked to neoplasm.